109173 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
#1202Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers
#1203Multimeric oligonucleotides compounds having cleavable linkers
#1204Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
#1205Deep intronic target for splicing correction on spinal muscular atrophy gene
#1206Compositions and methods for modulation of FGFR3 expression
#1207Compositions and their uses directed to huntingtin
#1208Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#1209MICROMIRs
#1210Multimeric oligonucleotides compounds
#1211MODULATION OF CD40 EXPRESSION
#1212Antisense compounds targeting genes associated with fibronectin
#1213Method of promoting wound healing
#1214Therapeutics with conformationally restricted monomers
#1215Modified cytosine polynucleotide oligomers and methods
#1216Methods and compositions for inhibition of immune responses and autoimmunity
#1217Oligonucleotide conjugates
#1218Methods for modulating C9ORF72 expression
#1219Oligomeric compounds comprising bicyclic nucleosides and uses thereof
#1220Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#1221Oligomeric compounds comprising tricyclic nucleosides and methods for their use
#1222Short interfering ribonucleic acid (siRNA) for oral administration
#1223Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#1224Compositions and methods for modulating SMN gene family expression
#1225Euchromatic region targeting methods for modulating gene expression
#1226UNA oligomers targeting micro-RNA for therapeutics
#1227Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
#1228UNA duplex oligomers for therapeutics
#1229Methods targeting miR-128 for regulating cholesterol/lipid metabolism
#1230TARGETING OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING FXN RNA
#12315' TARGETING OLIGONUCLEOTIDES FOR MODULATING RNA
#1232METHODS FOR MODULATING RNA USING 5' TARGETING OLIGONUCLEOTIDES
#1233Methods for use in modulating miR-122A
#1234COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#1235Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#1236Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#1237METHODS FOR SELECTIVE TARGETING OF HETEROCHROMATIN FORMING NON-CODING RNA
#1238Selective reactivation of genes on the inactive X chromosome
#12393' TARGETING OLIGONUCLEOTIDES FOR MODULATING RNA
#1240Selective inhibition of polyglutamine protein expression
#1241Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#1242Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same
#1243COMPOSITIONS AND METHODS FOR MODULATING APOA1 AND ABCA1 EXPRESSION
#1244Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
#1245Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#1246Modulation of enhancer RNA mediated gene expression
#1247Compositions and methods for inhibition of nucleic acids function
#1248COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION
#1249Compositions and methods for modulating ATP2A2 expression
#1250Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#1251Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#1252COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION
#1253RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1254OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOSIDES AND HAVING REDUCED TOXICITY
#1255Antisense modulation of GCCR expression
#1256Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
#1257COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#1258COMPOSITIONS AND METHODS FOR MODULATING BDNF EXPRESSION
#1259Compositions and methods for modulating hemoglobin gene family expression
#1260Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
#1261Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#1262Micro-RNA inhibitors and their uses in disease
#1263RNA products and uses thereof
#1264MicroRNA compounds and methods for modulating miR-122
#1265Antisense compounds targeting genes associated with fibronectin
#1266Compositions and methods for gene silencing
#1267Antisense modulation of GCGR expression
#1268Compositions and methods for modulating UTRN expression
#1269Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#1270Micro-RNAs involved in macular degeneration
#1271Targeting micrornas for the treatment of fibrosis
#1272Antisense conjugates for decreasing expression of DMPK
#1273COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB
#1274INHIBITORS OF NOX4 EXPRESSION AND /OR NOX4 FUNCTION AND THEIR USE IN THE PREVENTION AND TREATMENT OF NERVE INJURY AND/OR NEUROPATHIC PAIN
#1275Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#1276Targeting MicroRNAs for metabolic disorders
#1277TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF
#1278Compounds and methods for enhanced cellular uptake
#1279MODULATION OF RNA BY REPEAT TARGETING
#1280RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
#1281Therapeutic nanoparticles and methods of use thereof
#1282CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY
#1283Modulation of hepatitis B virus (HBV) expression
#1284Materials and methods related to modulation of mismatch repair and genomic stability by miR-155
#1285MICRORNAS AND USES THEREOF
#1286MicroRNA compounds and methods for modulating miR-122
#1287Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1288Modulation of signal transducer and activator of transcription 3 (STAT3) expression
#1289Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
#1290Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#1291Selective antisense compounds and uses thereof
#1292COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION AND USES THEREOF
#1293tRNA derived small RNAs (tsRNAs) involved in cell viability
#1294Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
#1295ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
#1296Stabilized STAT3 decoy oligonucleotides and uses therefore
#1297Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof
#1298Oligonucleotides for treating expanded repeat diseases
#1299Control of whole body energy homeostasis by microRNA regulation
#1300Antisense antiviral compound and method for treating influenza viral infection
#1301Chimeric double-stranded nucleic acid
#1302Complement antagonists and uses thereof
#1303Antisense design
#1304Tricyclo-phosphorothioate DNA
#1305Methods of using microRNA 195 in providing neuroprotection
#1306Potent LNA oligonucleotides for the inhibition of HIF-1a expression
#1307Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#1308MicroRNA-based methods and assays for osteosarcoma
#1309Therapeutic nanoparticles and methods of use thereof
#1310Short interfering RNA (siRNA) analogues
#1311Micrornas in neurodegenerative disorders
#1312Antisense modulation of PTP1B expression
#1313Methods for modulating factor 12 expression
#1314Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#1315Methods for modulating kallikrein (KLKB1) expression
#1316Methods for modulating kallikrein (KLKB1) expression
#1317Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
#1318Methods of modulating MicroRNAs in the treatment of pulmonary arterial hypertension
#1319Spinal muscular atrophy treatment via targeting SMN2 catalytic core
#1320Diagnosis and treatment of friedreich's ataxia
#1321Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#1322Modulation of hepatitis B virus (HBV) expression
#1323MicroRNA compounds and methods for modulating MIR-21 activity
#1324Modulation of androgen receptor expression
#1325SiRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
#1326MiR-33 inhibitors and uses thereof to decrease inflammation
#1327Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#1328Methods targeting miR-128 for regulating cholesterol/lipid metabolism
#1329Composition containing antisense oligonucleotide to micro RNA
#1330Antimir-451 for the treatment of polycythemias
#1331Modulation of alpha synuclein expression
#1332Inhibitors of the miR-15 family of micro-RNAs
#1333Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#1334Base modified oligonucleotides
#1335Compounds and methods for modulating interaction between proteins and target nucleic acids
#1336Antisense modulation of fibroblast growth factor receptor 4 expression
#1337Antagonat compositions and methods of use
#1338Methods targeting miR-33 microRNAs for regulating lipid metabolism
#1339RNAi sequence-independent modification formats, and stabilized forms thereof
#1340Modifications for antisense compounds
#1341Compositions, kits and methods for treatment of cardiovascular, immunological and inflammatory diseases
#1342Nucleic acid having an anti-metabolic syndrome effect
#1343Short interfering ribonucleic acid (siRNA) for oral administration
#1344Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
#1345Segmented micro RNA mimetics
#1346RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1347Oligonucleotides comprising alternating segments and uses thereof
#1348TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF
#1349Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
#1350Compounds and methods for modulating expression of DGAT2
#1351Nuclease resistant double-stranded ribonucleic acid
#1352Antisense modulation of GCCR expression
#1353Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
#1354Antisense modulation of GCGR expression
#1355Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
#1356MicroRNA as a cancer progression predictor and its use for treating cancer
#1357ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
#1358Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#1359Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#1360Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155
#1361METHODS AND COMPOSITIONS USEFUL IN TREATMENT OF DISEASES OR CONDITIONS RELATED TO REPEAT EXPANSION
#1362Selective reduction of allelic variants
#13635′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
#1364Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#1365Modulation of Hepatitis B virus (HBV) expression
#1366Modulation of angiopoietin-like 3 expression
#1367Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#1368Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#1369Oral delivery of therapeutically effective LNA oligonucleotides
#1370AGENTS, COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIES IN WHICH REGULATING AN ACHE-ASSOCIATED BIOLOGICAL PATHWAY IS BENEFICIAL
#1371MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#1372RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3
#1373Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#1374TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY
#1375TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
#1376Antisense modulation of PTP1B expression
#1377Stabilized STAT3 decoy oligonucleotides and uses therefor
#1378Method of inhibiting miR-33 using a modified oligonucleotide
#1379Modulation of eIF4E expression
#1380Modulation of signal transducer and activator of transcription 3 (STAT3)expression
#1381MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
#1382Oligomeric compounds for the modulation of HIF-1A expression
#1383MicroRNA as a cancer progression predictor and its use for treating cancer
#1384Antisense oligonucleotides for inhibition of microRNA-21
#1385Bridged artificial nucleoside and nucleotide
#1386COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR
#1387Treatment of inflammatory diseases using miR-124
#1388MicroRNA inhibitors comprising locked nucleotides
#1389SPARC ANTISENSE COMPOSITIONS AND USES THEREOF
#1390Method for modulating responsiveness to steroids
#1391Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy
#1392TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE
#1393Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1394NUCLEIC ACID MOLECULES AND USES THEREOF
#1395TRICYCLO-DNA ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
#1396SOLUBLE THF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#1397Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#1398miR-31 in duchenne muscular dystrophy therapy
#1399Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
#1400Targeting MicroRNAs for metabolic disorders
#1401Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
#1402Antisense oligomers targeting PCSK9
#1403Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1404Potent anti APOB antisense compounds
#1405MIRNA AND ITS TARGETS RESPECTIVELY THE PROTEINS MADE BASED ON THE TARGETS AS A PROGNOSTIC, DIAGNOSTIC BIOMARKER AND THERAPEUTIC AGENT FOR CANCER
#1406Micro-RNA mediated modulation of colony stimulating factors
#1407Oligomeric compounds and compositions for the use in modulation of target nucleic acids
#1408Use of microrna-199b-5p in medical and diagnostic field
#1409Pharmaceutical Composition
#1410METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES
#1411Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#1412Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders
#1413OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#1414TREATMENT OF TRISTETRAPROLINE (TTP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TTP
#1415Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs
#1416Reduced size self-delivering RNAi compounds
#1417Method for inhibiting the activity of mir-155
#1418Short interfering ribonucleic acid (siRNA) for oral administration
#1419Short interfering ribonucleic acid (siRNA) for oral administration
#1420Short interfering ribonucleic acid (siRNA) for oral administration
#1421Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#1422METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS
#1423COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
#1424RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3 PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
#1425Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
#1426TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1427LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR
#1428Modulation of exon recognition in pre-mRNA by interfering RNA structure
#1429Compositions and their uses directed to huntingtin
#1430BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM
#1431Means and methods for counteracting muscle disorders
#1432ANTAGONISTS OF MIR-155 FOR THE TREATMENT OF INFLAMMATORY LIVER DISEASE
#1433SIRNA COMPOUNDS AND METHODS OF USE THEREOF
#1434Spinal muscular atrophy treatment via targeting SMN2 catalytic core
#14352'-F MODIFIED RNA INTERFERENCE AGENTS
#1436METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#1437Reduced size self-delivering RNAi compounds
#1438Compositions and methods for inhibition of nucleic acids function
#1439Nuclease resistant double-stranded ribonucleic acid
#1440RNA interference in skin indications
#1441Neutral nanotransporters
#1442SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#1443Oligomeric compounds for the modulation of HIF-1α expression
#1444RNA ANTAGONISTS TARGETING HSP70-2
#1445Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#1446Selective inhibition of polyglutamine protein expression
#1447Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#1448MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION
#1449ANTIDOTE OLIGOMERS
#1450Complement antagonists and uses thereof
#1451Modulation of CD40 expression
#1452Methods for treating androgen receptor dependent disorders including cancers
#1453RNA antagonists targeting Hsp27
#1454NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF
#1455RNA ANTAGONISTS TARGETING GLI2
#1456Antisense antiviral compound and method for treating influenza viral infection
#1457Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
#1458Double-stranded RNA directed to CASP2 and methods of use thereof
#1459SOLUBLE TNF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#1460siRNA compounds for inhibiting NRF2
#1461Modification of MYD88 splicing using modified oligonucleotides
#1462Oligomeric compounds comprising tricyclic nucelosides and methods for their use
#1463Compounds for the modulation of beta-catenin expression
#1464RNA antagonist compounds for the modulation of PIK3CA expression
#1465Compounds and methods for modulating expression of SGLT2
#1466MODULATION OF FACTOR 9 EXPRESSION
#1467RNA Antagonist Compounds for the Modulation of FABP4/AP2
#1468ENA nucleic acid drugs modifying splicing in mRNA precursor
#1469Methods and compositions for inhibition of immune responses and autoimmunity
#1470Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
#1471RNA Antagonist Compounds for the Modulation of MCL-1
#1472Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
#1473Antisense Oligonucleotides Against VR1
#1474MicromiRs
#1475POLYNUCLEOTIDE OR ANALOGUE THEREOF, AND GENE EXPRESSION REGULATION METHOD USING THE POLYNUCLEOTIDE OR THE ANALOGUE THEREOF
#1476Pharmaceutical composition comprising anti-mirna antisense oligonucleotide
#1477Combination treatment for the treatment of hepatitis C virus infection
#1478Method for inhibiting the activity of mir-155
#1479USE OF SHORT OLIGONUCLEOTIDES FOR REAGENT REDUNDANCY EXPERIMENTS IN RNA FUNCTIONAL ANALYSIS
#1480SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA
#1481Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#1482Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same
#1483LNA antagonists targeting the androgen receptor
#1484siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
#1485AGENTS, COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIES IN WHICH REGULATING AN ACHE-ASSOCIATED BIOLOGICAL PATHWAY IS BENEFICIAL
#1486Short oligomer antagonist compounds for the modulation of target mRNA
#1487Nicked or gapped nucleic acid molecules and uses thereof
#1488Antisense compounds
#1489Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#1490MODULATION OF eIF4E EXPRESSION
#1491SMALL INTERFERING RNA (SIRNA) TARGET SITE BLOCKING OLIGOS AND USES THEREOF
#1492NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF
#1493Compositions and methods for gene silencing
#1494Oligomeric compounds for the modulation of HIF-1alpha expression
#1495COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#1496Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
#1497NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF
#1498NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF
#1499Novel tyrosinase-specific anti-gene oligonucleotides as depigmenting agents
#1500HYBRIDIZATION-STABILIZING CONSTRUCT